The Biden-Harris administration has committed to reviving the Cancer Moonshot Initiative, according to a White House press briefing that was hosted on Wednesday, February 2, 2022.

The program, which was first initiated by President Joe Biden in 2016 during his vice presidency with the Obama administration, encompasses efforts to increase screening rates, address inequity, fast track clinical trials, and support advances like using mRNA to target cancer with the goal of reducing the age-adjusted mortality rate associated with cancer by at least 50% over the next year.

The administration hopes that these efforts will improve the experience of people and families who are living with and surviving cancer.

Following the initial launch of the Cancer Moonshot program in 2016, novel efforts to investigate immune-oncology, cancer drug sensitivity and resistance, pediatric cancers, patient engagement, cancer health disparities, and clinical implementation science, as well as the funding of the Human Tumor Atlas Network, have been supported and sustained by the National Cancer Institute. Furthermore, the launch created more than 70 initiatives, 240 projects, and 69 million hours of analysis spanning between 2013 and 2020, engaging over 70,000 users each month.

“[Because of] the progress over the last 25 years, the death rate has fallen by more than 25%, but despite the progress of lives extended and lives saved cancer is still the number 2 cause of death in America,” President Joe Biden said in a press release.

"We’ll bring a fierce sense of urgency to the fight against cancer," he added. "I refuse to believe this is beyond our capacity. I refuse to believe it."

Issue a call to action on cancer screening and early detection;

Host a White House Cancer Moonshot summit;

Build on a White House cancer roundtable conversation series; and

Require an all-hands-on-deck approach with the help of the private sector, foundations, academic institutions, health care providers, and all Americans.

With these efforts, the White House hopes to:

Increase screening access to promote early diagnoses;

Explore avenues in cancer prevention—including research with mRNA vaccines;

Address and reduce inequities in health care;

Increase targeted treatment options and availability;

Focus energy on rare and less understood cancers—including pediatric cancer; and

“I can confidently say that this is the most exciting moment in the history of our field,” said Edjah Nduom, MD, FAANS, associate professor, Department of Neurosurgery, Winship Cancer Institute of Emory University, during the White House briefing, where he referred to the president as the country’s “patient advocate in chief.”

“We have identified several research areas that warrant prioritization in a Moonshot 2.0 initiative,” David B. Agus, CEO of the Lawrence J. Ellison Institute for Transformative Medicine and lead author of an editorial published in 

, which called for another Moonshot effort, concluded. “Research in these priority areas could also identify ways to take advantage of real-world data and facilitate access to quality care for individuals in low socioeconomic and rural areas who have received a disproportionately lower benefit from advances during the past 7 years.”

Biden to relaunch cancer moonshot, hoping to cut deaths by 50%. Axios. February 2, 2022. Accessed February 4, 2022. 

Fact sheet: President Biden reignites cancer moonshot to end cancer as we know it. The White House. February 2, 2022. Accessed February 4, 2022. 

Agus DB, Jaffee EM, Dang CV. Cancer Moonshot 2.0. 

. 2021;22(2):P164-165. doi:10.1016/S1470-2045(21)00003-6s

President Biden hosts an event at the White House to reignite the Cancer Moonshot. Youtube. February 2, 2022. Accessed February 4, 2022. 

https://www.youtube.com/watch?v=M9Yc_zKb5N8

Gangitino A. Biden relaunches cancer moonshot: “Let’s end cancer as we know it.” The Hill. February 2, 2022. Accessed February 4, 2022. https://bit.ly/3IUhHLk

Articles

The program is designed to reduce the age-adjusted death rate associated with cancer by at least 50% over the next 25 years.

 President Biden Vows to Revive Cancer Moonshot Program

A predictive model demonstrated that cervical cancer may soon be almost entirely prevented in communities with low poverty rates. However, this elimination may not apply to communities with high poverty rates, according to data published in the journal of 

Cancer Epidemiology, Biomarkers & Prevention

Specifically, it is estimated that this disease subtype may be virtually eliminated by 2030 in low poverty American communities. The anticipated time in high poverty communities is unfortunately doubled, with the model predicting a near elimination by 2044 in these areas.

“Other studies have predicted that, as a whole, the U.S. will hit the elimination target in the middle of that range. The fact that some places will hit it a decade before other places is a little bit of a ‘gut punch,’” commented Jennifer Spencer, PhD, an assistant professor at the University of Texas at Austin, who performed this work as a research fellow at the Harvard School of Public Health, in a press release.

In the United States, roughly 14,000 cases of cervical cancer are diagnosed every year and there are estimated to be around 4,000 case-related deaths. Human papillomavirus (HPV) infections are the cause behind over 90% of cervical cancer diagnoses. HPV is a sexually transmitted infection that can also cause anal, penile, vaginal, vulvar, and oropharyngeal tumors.

Since 2006, available HPV vaccines have served to protect against 9 different HPV types, including 7 out of the 14 which are associated with an increased risk of cancer. All adolescents are advised to receive a full vaccination, which consists of 2 doses for children aged 9 to 15 and 3 doses for individuals between 15 and 26 years of age. According to the World Health Organization, a “near-elimination” of cervical cancer equates to less than 4 cases per 100,000 individuals. The vaccine is over 90% effective in preventing HPV-related cancers and is therefore expected to help the United States reach “near-elimination” status.

However, most patients do not develop cervical cancer until they are older than 30 years old. Therefore, scientists are not yet able to quantify the effects of widespread vaccination effort—the first round of vaccinated adolescents are only now beginning to enter the age range of increased risk. Because of this, researchers have turned to tools like predictive models.

Spencer and her colleagues used previous models to design a model of HPV spread and progression. The model considered the risk of HPV transmission among vaccinated vs unvaccinated individuals, the probably of HPV progressing to cervical cancer, rates of cervical cancer screenings, and the odds of effective cancer treatment.

The model was designed into 2 separate versions. One represents a hypothetical county in the lowest poverty quartile while the other represents one of a county in the highest poverty quartile. Researchers used immunization data from the National Immunization Survey-Teen (NIS0Teen), screening and follow-up data from the National Health Interview Survey (NHIS), and HPV prevalence data from the National Health and Nutrition Examination Survey (NHANES), to compare immunization data between low and high poverty areas.

The results predicted that there will be 21,604 excess cases of cervical cancer in high-poverty areas compared with those in low-poverty areas. Despite this, the rate of excess cases is still believed to improve. Specifically, the disparity in excess cervical cancer rates in high-poverty areas is anticipated to decrease from 2.5 excess cases per 100,000 women to an excess of 1.0 case per 100,000 women by 2070. Although the model did not demonstrate that near elimination would be achieved sooner if vaccination rates reached 80%, vaccination efforts are still predicted to reduce around 1,000 excess cases over the next 50 years.

Limitations of this study include the fact that the model only accounted for heterosexual transmission, and it did not factor in infections with more than one type of HPV, which could alter vaccine efficacy predictions. Additionally, the authors acknowledge that, in the coming years, an improved understanding of disease progression following HPV infection and cervical cancer carcinogenesis could affect the accuracy of these predictions.

“Vaccination can do a lot of good, but it’s unlikely that the disparities can be addressed through just vaccination,” concluded Spencer. “The next step is to identify what policies we can use to close these gaps in the future.”

Low-poverty U.S. communities may eliminate cervical cancer by 2030 but high-poverty communities may lag behind. American Association for Cancer Research. News release. September 9, 2021. Accessed January 17, 2021. 

As the HPV vaccine becomes more prevalent, cervical cancer rates are expected to decrease significantly by 2030. However, this trend may differ across socioeconomic communities. 

Cervical Cancer Advances May Heighten Preexisting Health Disparities

The significance of cancer screening is undeniable. With routine testing, there is an increased chance of detecting cancer early when it is most treatable. Not only can screening identify cancer at its earliest stages, it can also find abnormalities before they become malignant.

Due to COVID-19, access to potentially lifesaving tests have been reduced. In the beginning of the pandemic, many patients throughout the United States were challenged with the decision to risk exposure to the novel coronavirus, or delay their medical care. At the same time, some cancer screening centers were closed. Updated guidelines suggested to postpone certain procedures to reduce the possibility of infection. States issued stay-at-home orders and across the country there was apprehension to enter medical facilities. These influences led to a sharp decline in cancer screenings. According to one study, at the beginning of the pandemic, breast, colon, lung and prostate cancer screenings decreased by 85%, 75%, 56% and 74% respectively, compared to the previous year.1

To many professionals in oncology, this trend was alarming. Without screening, new cancers may not be detected and treatment may be deferred. This disruption could lead to cancer being diagnosed at an advanced stage and the need for more complex medical care. Consequent negative impacts and adverse outcomes could result for years to come.1

Being aware of the effect of COVID-19 allows for the opportunity to help people overcome existing uncertainties. We can provide education on the importance of screening, and how to do so safely. Using guidance from the Centers for Disease Control and Prevention (CDC), we can equip patients with the tools they need to return to the doctor’s office confidently. This direction includes protective measures taken in a public health clinical setting to ensure risk of exposure is minimized.2 Patients will understand how to protect themselves, while feeling their doctors are prioritizing their well-being.

Health care professionals should consider how cultural and environmental conditions contribute to access to screening. Understanding barriers to care is crucial to efficiently empower patients. Social determinants of health, including race, ethnicity, education, insurance status, employment and location all shape a patient’s ability to get screened for cancer. Although these factors have been present pre-pandemic, COVID-19 has highlighted and often accentuated the fact that these inequalities exist.3

Overall, the COVID-19 pandemic disproportionally affected medically underserved populations, including communities of color.3It has been previously established that there are racial disparities in cancer screening for Black and African American patients, as well as Hispanic patients. During the pandemic, access to cancer screening dropped at higher rates within these populations. Existing fears or mistrust of doctors were compounded by new ones related to COVID-19. Lack of access to care was exacerbated by COVID-19-related changes to public transportation, work schedules or the loss of employment and insurance within these groups.3 If these health disparities are ignored, it is impossible to create comprehensive solutions for cancer screening.

Although there has been improvement in cancer screenings since the beginning of the pandemic, it is our responsibility to make substantial attempts to address gaps to care. To maintain the momentum of recovery, inequities have to be acknowledged. Health care professionals should recognize disparities and contribute to efforts that expand access. There is a necessity to implement outreach, continue campaigns and offer education—especially for vulnerable communities. These initiatives are crucial in getting resources to underserved areas.4 Furthermore, to be successful, programs must be done in a culturally and linguistically appropriate manner.

Time to Screen is an example of a national campaign encouraging people to take control of their health by getting recommended cancer screenings back on track. This collaboration between Cancer

 and the Community Oncology Alliance stresses the importance of screening, educates the public on getting screened safely and provides guidance on getting connected to care. Delivering this service through a health disparities lens, patients will learn how to overcome barriers and obtain their screening. Through these continued efforts, we will be able to make positive impacts and ensure equitable resources to individuals in need. 

For more information on Time to Screen, you can call 1-855-53-SCREEN or go to 

Marissa Fors is Director of Specialized Programs at CancerCare.

 is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. Our comprehensive services include case management, counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All Cancer

 services are provided by master’s-prepared oncology social workers and world-leading cancer experts.

Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors. 

. 2020; 4:1059-1071. doi:10.1200/CCI.20.00134

Public Health Activity Guidance.Centers for Disease Control and Prevention.April 8, 2020. Accessed December 15, 202. https://bit.ly/3Fs1nPW

Carethers M, Sengupta R, Blakey R, Ribas A, D’Souza G. Disparities in cancer prevention in the COVID-19 era.

. November 1 2020; 13 (11) 893-896; doi: 10.1158/1940-6207.CAPR-20-0447

Marabella C. Cancer screenings recover from height of COVID-19 pandemic, but disparities remain. OncLive. August 19, 2021. Accessed December 15, 2021. 

Early detection is key to improving prognosis and achieving better outcomes for patients. 

Addressing the Impact of COVID-19 and Health Disparities on Cancer Screening

Improving cancer screening in rural areas poses certain challenges not always seen in more populated settings. However, oncology nurses are adept at way-finding, particularly when the need is great. Early detection and treatment of cancer saves lives, yet for residents living in outlying and rural areas, risk factors for developing cancer tend to be greater than in urban areas, whereas screening rates are lower.

Factors contributing to these disparities include differences in accessibility to care, lifestyle, culture, and financial stability.

The COVID-19 pandemic, which resulted in delays of care across the geographical spectrum, hit rural areas hard, as financial strain forced out some providers or led to closures of numerous clinics and hospitals.

While the impact of the pandemic on cancer detection and treatment is not yet fully known, the need to improve screening in rural areas remains unquestionably urgent.

So what can be done to address this issue? To answer this question, 

® spoke with several oncology nurses who took on the challenge to improve rural cancer screening. Their efforts are inspiring and underscore the value of collaboration, innovation, and determination.

Carol Estwing Ferrans, PhD, RN, FAAN, is professor merita at the University of Illinois Chicago College of Nursing. She has coauthored numerous publications addressing rural cancer care, including an article with lead author Leslie Carnahan, MPH, PhD, on rural cancer disparities.

 She shared with us her experience and success improving cancer screening and early detection in the Chicago area and described disparities inherent in rural communities.

With grant money awarded from the National Institutes of Health (NIH), Ferrans and her colleagues set out to reduce late-stage breast cancer diagnoses, particularly among African American women in Chicago. “Fear is a huge barrier to screening,” Ferrans said. “When people are afraid of what screening may reveal, they are reluctant to participate. We addressed this barrier by producing a 14-minute video, ‘Beating Breast Cancer,’ featuring 5 beautiful African American women—all breast cancer survivors—telling their stories.”

The video, in addition to allaying fear, was created to clear up misconceptions pertaining to breast cancer and resonate with the intended target audience. As women responded to the cancer screening promotion, they were shown the video or provided the link to watch at home. The intervention worked. Thousands of women throughout Chicago responded, not only by completing cancer screening but also by following up as when recommended. The 5-year campaign and other such efforts were so successful, Chicago saw a 14% reduction in breast cancer death rates for African American women, more than any other major city in the US.

Motivated by the impressive results of the work done in Chicago, Ferrans has now shifted her attention to rural Illinois, where she will be working to reduce disparities alongside colleague Yamilé Molina, PhD, MS, MPH, who is spearheading the effort and seeking additional NIH grant money. Regarding barriers to care in rural communities, Ferrans explained that the work they’ve done has shown 4 primary drivers of cancer disparities. Lack of insurance stands as a major factor. “We think about farmers with large farms, and [although] they may have wealth tied up in their farms, people in rural areas often struggle with collective poverty and no insurance,” Ferrans said. Migrant workers are another concern, as they often have language barriers and are also without insurance. Culturally, there is a rural reluctance to go on public aid or use government resources, making these issues tricky to address. For people with insurance, their deductibles are often too high or screening isn’t covered. Some make too much money for Medicaid but not enough for insurance and slip between the cracks.

Lack of cancer resources in the community, such as mammography centers and oncology specialists, poses another challenge. Clinic closures and consolidations further reduce screening and treatment access. “It’s difficult when few specialists are available. Wait times are long, [and] it might take 2 months to see a specialist or have an initial visit,“ Ferrans said. “Delays in detection can advance cancer, setting up for later-stage diagnosis.”

Residents in rural communities may also face long travel times and associated fuel costs. Some have little or no time off from work or unreliable transportation.

The fourth disparity driver is fear, and although it’s not unique to residents in rural areas, it may be experienced differently. Rural residents may delay medical evaluation after finding symptoms, especially as COVID-19 continues to make its way through these communities. For many, the fear of cancer in addition to a COVID-19 diagnosis can be immobilizing.

These barriers may seem insurmountable, but Ferrans was quick to point out the hope and good news. “Nurses are making a difference. Nurses are doing what nurses do. They build relationships in the community, and they build trust. They fill the gaps. They understand the strength and value of family,” she said.

The same approaches used in urban areas can be used in rural settings when tailored and targeted for the community. These include personal engagement and communicating via phone, Zoom, and telehealth technologies. Residents in rural communities are used to communicating via these methods because of the distance factor, even more so since the pandemic. Ferrans suggests creating videos specifically for the rural audience and their concerns.

Nurses can guide people to resources, allay their fears, confront misconceptions, direct them to safety net resources, get them fast-tracked to medical care, and connect them to free or low-cost screening programs and diagnostic follow-ups. “Nurses are doing this work, we just need more,” Ferrans said. “They have a unique role and the tools in their pocket. We have reason for hope.”

Carnahan’s work also focuses on rural disparities from a holistic approach, including working on Centers for Disease Control and Prevention (CDC)-funded programs for breast and cervical cancer screening and early detection and cancer prevention program evaluations for the Illinois Department of Public Health, and the development and implementation of a community engagement strategy for the forthcoming 2022-2027 Illinois Comprehensive Cancer Control Plan. She works in Chicago but maintains connections in the rural space and is working on a number of statewide evaluation projects. Through her work, Carnahan found that local programs often do not go far enough to address the financial disparities of underinsurance, but national programs are in place to help meet these gaps in coverage. The National Breast and Cervical Cancer Early Detection Program is one example.

“Nurses are positioned to facilitate the linkage between patients, programs, and resources,” Carnahan said.

In rural communities, some of the outreach and support services available provide transportation to screening services, which can address one of the barriers to care. When patients worry about who will pay for a biopsy if needed, nurses can discuss the different available resources and ensure patients’ financial concerns are addressed. Carnahan urges use of telehealth for risk assessment, for which primary care nurse involvement can be helpful. Partnering with public health nurses and helping develop and sustain a strong nursing workforce will be vital as the fallout from COVID-19, including delayed screenings, becomes more evident.

Marsha Woodall, DNP, MBA, RN, is a professor and Nurse Administrator Division chair at Madisonville Community College in Kentucky. She is the lead author of an article on improving education and screening in a rural population.

 Her insight on improving cancer screening in rural settings demonstrates how impactful interventions can be when using a carefully targeted and
tailored approach.

Woodall had participated in rural community outreach before, handing out pamphlets and informational brochures, signing up residents for screening, and chatting with community members during monthly events. Her booth featured a bagged cancerous lung that residents could see and touch, along with a walk-through depiction of a real colon with cancerous nodules. Although the approach was attention grabbing and engaging, follow-through was poor in response to screening tests handed out.


For her doctoral project, Woodall chose to employ a different and much more effective approach. She scheduled a meeting with the Madisonville mayor and asked for permission to visit every city department over 3 weeks to provide education about colorectal cancer. Focused on this target population, Woodall, along with a nurse navigator from Baptist Health Deaconess Madisonville, educated 193 city employees at the sewer plant, trash, water, and electric departments. Sessions were scheduled to align with department meetings during day, evening, and night shifts, making it convenient for employees to attend. They provided basic education and written materials about colon cancer. Pre- and posttests were completed to assess change in knowledge.

“They seemed to really be engaged,” Woodall said. “A few shared stories of a relative or friend that had been diagnosed with colon cancer and spoke out about the importance of screening.”

Half the attendees took home fecal immunochemical tests provided by the oncology nurse navigator, which detect occult blood in the stool. Twenty-nine submitted their tests, a return rate double that of the earlier community booth event. Eight tests were positive and were referred for follow-up.

Woodall encourages nurses to make it easy for rural residents to learn about cancer and participate in cancer screening. “Make it as hassle free and convenient as possible,” she said. She also stresses the importance of collaboration.

“It takes a team effort, but increasing cancer screening in rural communities is absolutely doable by utilizing a targeted approach and exercising persistence.” 

Preventing and treating cancer in rural America. CDC. April 24, 2018. Accessed November 10, 2021. https://www.cdc.gov/ruralhealth/docs/Policy-Brief-Cancer-H.pdf

Cancino RS, Su Z, Mesa R, Tomlinson GE, Wang J. The impact of COVID-19 on cancer screening: challenges and opportunities. 

Carnahan LR, Abdelrahim R, Ferrans CE, Rizzo GR, Molina Y, Handler A. Rural cancer disparities: understanding implications for breast and cervical cancer diagnoses. 

. 2021;25(5):10-16. doi:10.1188/21.CJON.S1.10-16

Woodall M, DeLetter M. Colorectal cancer: a collaborative approach to improve education and screening in a rural population. 

. 2018;22(1):69-75. doi:10.1188/18.CJON.68-75

Longer travel times and fewer available resources can make rural cancer care particularly challenging, but oncology nurses may play a crucial role in promoting screenings in these areas.  

Collaboration, Determination Improves Cancer Screenings in Rural Areas

Cisplatin is a life-saving drug, says Bruce Carleton, PharmD, FCP, FISPE. However, although the drug has lifesaving benefits, it also causes some degree of hearing loss in about 60% of children who receive this therapy. Furthermore, about 40% of children who receive cisplatin require hearing aids for the rest of their lives as a result of treatment.

In this episode of “The Vitals,” Carleton, of the Department of Pediatrics, Division of Translational Therapeutics, at the University of British Columbia, spoke with 

® about balancing the beneficial effects of cisplatin with it’s potential to cause permanent hearing loss, in children with solid tumors. He discusses a study he recently co-authored, whose findings indicate that children under the age of 5 years are at an increased risk of developing hearing loss because of this treatment, compared with children older than the age of 5, as well as comments on how genetics may one day play a role in reducing the risk of hearing loss in this patient population.

The study assessed 368 pediatric patients with cancer by conducting over 2000 audiological assessments before, during, and after receiving cisplatin treatment. Three years after starting therapy, 75% of patients aged 5 years and younger, and 48% of patients aged older than 5 years had experienced cisplatin-induced hearing loss. According to Carleton, these findings demonstrate a need for routine audiological assessments for children who receive this treatment.

“At the end of every cycle, we should [conduct] a hearing assessment, and we should follow the toxic course of this drug,” he says. “The legitimate concern among some clinicians is that if patients or parents know that their child is developing hearing loss, they're more likely to say, ‘Do we really have to give them this cisplatin?’”

Podcasts

On this episode of “The Vitals,” an expert in genetics discusses ongoing research to address cisplatin-induced hearing loss in pediatric patients with cancer.


Balancing the Benefit and Toxicity of Cisplatin in Young Children with Cancer

The FDA has approved the drug abatacept (Orencia) in combination with certain immunosuppressants to prevent moderate to severe acute-graft-vs-host disease (aGVHD) for patients at least 6 years of age who have received unrelated donor hematopoietic stem cell transplant. Abatacept is designed to inhibit specific protein targets and prevent donor T-cells from attacking healthy tissues posttransplant.

Abatacept is the first agent to receive regulatory approval for prevention of this condition, and the decision was supported by real-world evidence as a component detailing its clinical efficacy.

“Acute graft versus host disease can affect different parts of the body and become a serious post-transplant complication,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, stated in a press release. “By potentially preventing the disease, more patients may successfully undergo bone marrow or stem cell transplantation with fewer complications.”

The double-blind, placebo-controlled GGVHD-1 trial compared the use of abatacept with placebo in a total of 186 patients who underwent stem cell transplantation from a matched unrelated donor. All patients also received immunosuppressive drugs. The research measured severe, defined as grade III to IV, aGVHD-free survival, overall survival (OS), and moderate-severe, defined as grade II to IV, aGVHD-free survival 6 months following transplantation.

Results showed that although abatacept did not significantly improve GVHD-survival vs placebo, at 87% vs 75%, respectively, it did improve OS rate, at 97% and 84%, respectively. With regard to moderate-severe aGVHD-free survival, patients in the investigative arm experienced a 50% rate vs 32% for those in the control arm.

Additional efficacy evidence came from the registry-based, GVHD-2 study, which leveraged real-world findings from the Center for International Blood and Marrow Transplant Research in patients who underwent stem cell transplantation from a mismatched unrelated donor.

In this effort, investigators evaluated outcomes from a total of 54 patients who recieved abatacept to prevent aGVHD, in combination with standard immunosuppressive drugs, compared with 162 patients who received standard immunosuppressive drugs alone. The study measured OS at 6 months post transplantation. OS rates in the investigative and control arms were 98% and 75%, respectively.

Regarding safety, the toxicities that were most frequently reported with abatacept included anemia, hypertension, cytomegalovirus (CMV) reactivation/CMV infection, fever, pneumonia, nosebleed, decreased levels of CD4 lymphocytes, increased levels of magnesium in the blood, and acute kidney injury.

The FDA also noted that those who receive the agent should be monitored for Epstein-Barr virus reactivation per institutional practices and they should receive preventative medication for Epstein-Barr virus infection prior to treatment initiation and for 6 months following transplantation. Patients should also be monitored for CMV infection/reactivation for 6 months after transplant.

FDA approves first drug to prevent graft versus host disease. News release. FDA. December 15, 2021. Accessed December 15, 2021. https://bit.ly/33zfoxR

Abatacept is now available for use in combination with certain immunosuppressants to prevent moderate to severe acute-graft-versus-host disease for select patients who have received unrelated donor hematopoietic stem cell transplant.

FDA Approves Abatacept to Proactively Treat Acute Graft-Versus-Host-Disease

Adults whose insurance covers lung cancer screenings were more likely to receive invasive screening procedures than patients in clinical trials, according to a study published in the 

. However, the out-of-pocket costs associated with downstream procedures may discourage adults with abnormal results to pursue their follow-up tests.

Among a group of 6,268 national employer-insured adults who received at least 1 low-dose CT scan (LDCT), 462 individuals (7.4%) followed up with a secondary or downstream procedure within the 12 months following screening.Women (adjusted odds ratio [aOR], 0.82; 95% CI, 0.68-0.99) and adults over the age of 65 (aOR, 1.62; 95% CI, 1.28-2.04) were more likely to follow-up with a downstream procedure.

The most common downstream procedure was a needle biopsy (69.0%), followed by cytology (23.6%), bronchoscopy (18.6%), and surgery (23.8%). A total of 93 patients (20.1%) received a lung cancer diagnosis following screening.

Overall, lung screening for this population costs $5,060,511.04 (an average of $740.06 perpatient). In comparison, the total out-of-pocket cost with this population was $427,069.74 ($62.46 per person.)

“[Out-of-pocket] costs associated with follow-up testing represents an underdiscussed risk, and the SDM should include patient financial consequences,” explained Tina D. Tailor, MD, Duke University Medical Center, Department of Radiology, and colleagues, in the study. “Given the existing disparities in lung cancer incidence and outcomes which cause disproportionate burden to vulnerable populations, failure to comprehensively address costs associated with [lung cancer screening] may disincentivize or discourage screening and/or necessary follow-up testing for certain populations. This may inadvertently widen existing lung cancer disparities.”

In 2010, the Patient Protection and Affordable Care Act (PPACA) was enacted. This requires non-grandfathered private and commercial insurers to cover USPSTF Grade A and B recommendations without cost-sharing. In addition, Medicare and most state Medicaid programs cover annual lung cancer screening with LDCT. Consequently, there has been a steady uptake in screening utilization since 2013.

In this study, researchers retrospectively analyzed data collected from patients between the ages of 55 and 79 who received screening between 2015 and 2017, noting the types and frequencies of downstream invasive procedures. Researchers then determined total costs per-episode (defined as a lung cancer screening exam and downstream procedure) and out-of-pocket costs using linear and logistic regression. Findings did not reveal an association between downstream procedures and race/ethnicity, poverty level, geographic division, or health plan type.

The out-of-pocket cost increased with each downstream procedure. The cost for these procedures managed between $0 and $342.05 with a median cost of $50.79. Of the 466 patients who received at least 1 follow-up procedure, 61% experienced an out-of-pocket cost.

Patients who received a lung cancer diagnosis at their consequent procedure paid an average of $332.24 and out-of-pocket costs for patients in this population ranged between $0 and $1,341.52. Those who did not pursue a downstream procedure after their screening did not experience out-of-pocket costs.

Notably, patients living in the Pacific region were more likely to have 0 out-of-pocket costs in comparison to patients in the East northern Central Region (OR, 1.67; 95% CI, 1.26-2.22). Patients living in the West-South Central Region were the least likely to have 0 out-of-pocket costs (OR0.76; 95% CI, 0.61-0.95).

Health plan types also impacted patient costs. Zero costs were associated with POS and PPO (OR, 0.67; 95% CI, 0.57-0.80) plans as opposed to HMO plans (OR, 0.49; 95% CI, 0.29- 0.83).

“Even a small [out-of-pocket] cost can induce burden among the financially fragile, such as those living at or below the federal poverty level, necessitating trade-offs between paying their cost share and other household or health expenses,” the study authors concluded. “Innovative insurance design needs to align insurance premiums or an [out-of-pocket] bundle covering the entire [lung cancer screening] episode to decrease the financial burden across the population of [lung cancer screening]-eligible individuals.”

Study authors acknowledged was limited by patients being required to have at least 12 months of continuous insurance coverage in 1 plan to be included. Consequently, patients switching insurances or who became uninsured during the study period were not included and therefore the procedural rates and costs may be underrepresented. Furthermore, the majority of included patients had POS health plans and the findings therefore may not be generalizable to other health plan types. Finally, costs did not consider procedure related complications. Further research should seek to address these factors to better assess the screening-related costs and expenditures.

Tailor TD, Bell S, Fendrick AM, Carlos RC. Total and out-of-pocket costs of procedures after lung cancer screening in a national commercially insured population: estimating an episode of care. 

J. American College of Radiology (accepted preproof). 

Available from: https://els-jbs-prod-cdn.jbs.elsevierhealth.com/pb-assets/Health%20Advance/journals/jacr/PreProofJACR_Manuscript_JACRAD-D-21-00091-1632519372147.pdf

A total of 7.4% of patients received a secondary or downstream procedure within the 12 months following their lung cancer screening.


Cost May Prevent Patients from Pursuing Procedures After Free Lung Cancer Screenings

The initial findings from the IMPACT study (NCT00261456) revealed that men who carry the 

 pathogenic variants are at an increased risk for prostate cancer compared with age-matched non-carrier individuals.

 The risk identified in these pathogenic variants, which are associated with Lynch Syndrome, highlight the potential value of regular prostate-specific antigen (PSA) screening starting at age 40.

“Prostate cancer screening isn’t recommended for the general population, but we believe it could benefit some groups of men at high inherited risk. Our new findings show that PSA testing in men with Lynch syndrome is much more likely to pick up life-threatening prostate cancer than in the general population,” Rosalind (Ros) Eeles, FMedSci, PhD, FRCP, FRCR, IMPACT study lead, professor of oncogenetics at The Institute of Cancer Research and a consultant in clinical oncology and oncogenetics at The Royal Marsden NHS Foundation Trust, said in a news release.

Lynch syndrome is characterized by pathogenic variants in 

which are mismatch repair genes. The familial cancer syndrome is associated with a predisposition to several cancers, including colorectal and endometrial. Data suggest that these genetic alterations confer an increased risk of early-onset, aggressive prostate cancer as well.

As such, the goals of the IMPACT study were to assess the utility of PSA screening in men with and without germline pathogenic variants in the genes in question, understand the incidence of prostate cancer among these men, and characterize tumors after the first round of screening.

The primary end point of the study was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of these pathogenic variants compared with non-carriers.

Overall, the international prospective study enrolled 828 men with mismatch repair gene pathogenic variants without a previous diagnosis of prostate cancer. Of these, 4 did not undergo PSA screening. Of the men who did undergo PSA screening, 203 were 

 non-carrier controls. An additional 134 

 non-carriers were randomly selected to increase the sample size for the non-carrier control groups.

Additionally, of the 828 men with confirmed pathogenic variants, 186 (19%) had a family history of prostate cancer.

Patients had to be between 40 and 69 years of age. They were required to have undergone genetic testing and tested positive or negative for known familial pathogenic variants. Men who had a 50% risk of inheriting a pathogenic variant but had not undergone genetic testing yet were eligible for enrollment.

Overall, patients were a median age of 53 years (range, 46-59). Most were of European ancestry (94%) and 41% were university graduates. Most patients did not have previous urinary symptoms (78%) or a previous PSA test (62%).

Men whose PSA level was higher than 3.0 ng/mL were offered a transrectal, ultrasound-guided prostate biopsy and histopathological analysis. Additionally, all participants are receiving at least 5 years of annual screening.

Within the first round of screening, 6% (n = 56) of men had a PSA concentration above 3.0 ng/mL and 4% (n = 35) underwent a prostate biopsy.

The results showed a prostate cancer incidence of 1.9% (n = 18; 95% CI, 1.1%-2.9%). The incidence of prostate cancer was 4.3% in 

 carriers (n = 13; 95% CI, 2.3%-7.2%), 0.5% in 

non-carriers (n = 1; 0.0%-2.6%), and 3% in 

 carriers (n = 4; 95% CI 0.8%-7.4%). No cases of prostate cancer were identified in 

Using a PSA threshold of more than 3.0 ng/mL, prostate cancer was detected more frequently among 

 carriers vs non-carriers (4.3% vs 0.5%; 

Ultimately, the positive predictive value of a prostate biopsy with a PSA threshold of 3.0 ng/mL was 51.4% (95% CI, 34%-68.6%). The positive predictive value of a PSA threshold of 3.0 ng/mL was 32.1% (95% CI, 20.3%-46%).

“Targeted screening has the potential to pick out aggressive prostate cancers at an early stage in men at high inherited risk, increasing their chances of survival. Because cancers in these men are more likely to be aggressive and potentially life-threatening, they would need to have radical treatment,” Eeles concluded. “I anticipate that these results, and evidence from our ongoing follow-up work, will influence future national and international screening guidelines for this group of men, with the aim of picking out prostate cancer earlier and potentially saving lives.”

Bancroft EK, Page EC, Brook MN, et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. 

. Published online October 19, 2021. Accessed October 29, 2021. doi:10.1016/S1470-2045(21)00522-2

Targeted prostate cancer screening could benefit men with inherited cancer syndrome. News release. The Institute of Cancer Research. October 19, 2021. Accessed October 29, 2021. 

This article was originally published on OncLive as “PSA Screening for Aggressive Prostate Cancer Supported in Men With Lynch Syndrome–Associated Pathogenic Variants”

The increased risk of prostate cancer associated with MSH2 and MSH6 pathogenic variants point to a need for annual PSA screening in men over the age of 40. 

Relationship Between MSH2, MSH6 and Prostate Cancer Incidence Highlights Value of PSA Screenings

Women between the ages of 25 and 42 years may be able to decrease their risk of developing early-onset colorectal cancer (CRC) by increasing their intake of vitamin D, according to results from a prospective cohort study published in 

Results showed that compared with women who consumed less than 300 IU of vitamin D daily, the HR was 0.51 (95% CI, 0.30-0.86) for those who consumed 300 IU to 450 IU daily, and 0.49 (95% CI, 0.26-0.93) for those who consumed 450 IU or more per day (

for trend = .01). No evidence of a nonlinear association was reported (

for nonlinearity = .50). Moreover, the HR per 400 IU/day increase was 0.46 (95% CI, 0.26-0.83).

“Vitamin D has known activity against CRC in laboratory studies. Because vitamin D deficiency has been steadily increasing over the past few years, we wondered whether this could be contributing to the rising rates of CRC in young individuals,” Kimmie Ng, MD, MPH, study author and director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute, stated in a press release.2 “We found that total vitamin D intake of 300 IU per day or more — roughly equivalent to three 8-oz. glasses of milk — was associated with an approximately 50% lower risk of developing young-onset CRC.”

Although the incidence of CRC has decreased in the United States and many other countries, the rate of adults younger than 50 years of age developing CRC has been on the rise. Due to delays in screening and other clinicopathologic features, cases of early-onset CRC tend to be is usually diagnosed at a more advanced stage. Moreover, although a large portion of early-onset cases do not have a family history of CRC, other known risk factors like obesity have been found to increase the risk of early-onset CRC.

Findings from previous studies have suggested that vitamin D intake may be a protective factor against CRC. However, it remains unknown whether vitamin D intake is linked with risk of early-onset CRC. With consumption of vitamin D–rich food, such as milk, fish, and eggs declining, investigators sought to examine whether vitamin D intake correlated with the risk of early-onset CRC.

To conduct this research, investigators analyzed data from the Nurses’ Health Study (NHS) II, a prospective cohort study of 116,429 female nurses between the ages of 25 years and 42 years. The trial began in 1989 and those enrolled on the NHS II study completed self-administered questionnaires every 2 years on demographics, lifestyle factors, and health-related information. These questionnaires were complemented by assessment of dietary intake through the use of food frequency questionnaires done every 4 years.

Those with inflammatory bowel disease, a previous diagnosis of CRC, implausible data for baseline energy intake or missing data for baseline vitamin D intake were not included in the analysis. Total vitamin D intake was calculated by adding dietary vitamin D intake and supplemental vitamin D intake from supplements or multivitamins.

Body mass index was calculated based on reported height and weight, with weight updated every 2 years. Investigators examined total energy, red meat, processed meat, fiber, calcium, folate, and alcohol. Smoking status was updated biennially for calculation of pack-years smoked. Physical activity was self-reported with questionnaires done every 2 to 4 years. Television viewing time was also used as a measure for sedentary behavior.

The primary end point for the study was the incidence of early-onset CRC, defined as CRC diagnosed before the age of 50 years.

“We also identified unreported lethal CRC cases through family members, the postal system, and the National Death Index. For all deaths due to CRC, we requested consent from the next of kin for acquisition of medical records,” the study authors wrote. “Physicians who were blinded to exposure status reviewed medical records to verify CRC diagnosis and recorded histopathologic findings and anatomic location.”

Of the 94,205 women studied, 111 cases of early-onset CRC during 1,250,560 person-years of follow-up were identified from 1991 to 2015, and the median vitamin D intake among them was 372 IU/day. Moreover, participants under the age of 50 years were less likely to have a high BMI, smoke cigarettes, consume alcohol, spend significant amounts of time watching television, or consume red meat. Additionally, these participants were more likely to consume more dietary fiber, folate, and calcium; use more aspirin and multivitamins; and be physically active and have healthy dietary habits.

Additional data showed that sources of vitamin D intake were inversely associated with reduced risk of early-onset CRC. A stronger association was observed for dietary vitamin D (HR per 400 IU/day increase, 0.34; 95% CI, 0.15-0.79) than supplemental vitamin D (HR per 400 IU/day increase, 0.77; 95% CI, 0.37-1.62). Moreover, vitamin D from dairy products was a significant contributor for this association (HR per 400 IU/day increase, 0.32; 95% CI, 0.12-0.84).

Investigators documented a total of 1,439 newly diagnosed conventional adenomas and 1,878 serrated polyps among participants younger than 50 years of age who had undergone a lower endoscopy from 1991 to 2011. Higher vitamin D intake was also associated with lower risk in this population. Compared with those who consumed less than 300 IU/day, the HR of any conventional adenoma was 0.71 (95% CI, 0.56-0.89) for those who consumed 600 IU/day or less, and the HR for any serrated polyp was 0.85 (95% CI, 0.70-1.03).

“Our results further support that avoiding low vitamin D status is important in younger adults for health and possibly CRC prevention,” study authors wrote. “If confirmed, our findings could potentially lead to recommendations for higher vitamin D intake as an inexpensive low-risk complement to CRC screening as CRC prevention strategy for adults younger than age 50.”

Kim H, Lipsyc-Sharf M, Zong X, et al. Total vitamin D intake and risks of early-onset colorectal cancer and precursors. 

. Published online July 7, 2021. doi:10.1053/j.gastro.2021.07.002

Shining new light on vitamin D and cancer. News release. Harvard University. August 17, 2021. Accessed August 20, 2021. 

This article was originally published on OncLive as “Increased Vitamin D Intake Associated With Lower Risk of Early-Onset CRC”

The data showed that a daily intake of around 300 IU of vitamin D — roughly the same as three 8-oz. glasses of milk — was linked to a nearly 50% decreased risk of early-onset colorectal cancer among women between the ages of 25 and 42 years.



Vitamin D Intake May Be Protective Against Early-Onset Colorectal Cancer

 showed a significant uptick in recent cancer screening procedures like mammography, PSA, Papanicolaou test, and low dose CT scan. This increase directly contrasts the low screening rates observed during the first pandemic peak.

Compared to pre-pandemic times, defined as December 2019 to March 2020, an increase in tests performed during period 7, defined as September 2020 to December 2020, was noted across all types of screening analyzed, with the exception of colonoscopy.

Specifically, these increases ranged from 2.0% for the Papanicolaou test to 24.0% for the prostate-specific antigen test. In this same time range, an increase in positive diagnoses was also observed across all categories, except for colonoscopy; that increase ranged from 1.0% to 38.0%.

During period 7, the number of colonoscopy tests dropped by 15.0%, and the number of associated diagnoses also dropped by 30.0% when compared with pre-pandemic times. A reduction in the number of screening tests was reported during periods 5 and 6, defined as March 2020 to June 2020 and June 2020 and September 2020, respectively; this decrease ranged from 65.0% to 82.0%, respectively, and 4.0% to 44.0%, respectively.

Moreover, significant shifts were observed with regard to racial distribution of patients undergoing mammography in period 6, defined as June 2020 to September 2020, and period 7, defined as September 2020 to December 2020, vs 3 months pre-pandemic. Higher proportions of non-Hispanic White patients were noted in these 3 time periods, at 83.2% and 82.0% vs 79.0%, respectively (

 < .001). Lower proportions of non-Hispanic Blacks were noted, at 5.2% and 5.3% vs 6.3%, respectively (

 < .001), as well was Hispanic/Latino patients, at 2.4% and 2.6% vs 3.3% (

The racial disparities were illustrated by reduced numbers of non-Hispanic Black and Hispanic patients undergoing mammography during period 7 (n = 1774 and n = 867, respectively) vs the 3 months before the pandemic (n = 1859 and n = 977, respectively; this contrasted with the increase in mammography tests in the whole group of patients analyzed. This finding was further validated by comparably significant shifts observed during periods 6 and 7 vs other pre-pandemic time periods.

“Although the overall increase in screening examinations is reassuring, the decrease in colonoscopy has yet to compensate,” the study authors wrote. “This highlights the importance of home-based alternatives for colon cancer screening in such particular situations. Racial disparities appear to differ between screening procedures, and they are more marked in patients undergoing mammography. Efforts to address these gaps are strongly required to ensure timely and equitable care across the patient population.”

Increases were detected in all cancer screening procedures except for colonoscopies. 

Prevention